SCM
ABOS icon

Silverarc Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Silverarc Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-146,922
Closed -$597K – 83
2023
Q1 		$597K Sell
146,922
-148,193
-50% -$774K 0.25% 62
2022
Q4 		$1.59M Sell
295,115
-124,885
-30% -$839K 0.46% 56
2022
Q3 		$4.21M Buy
+420,000
New +$2.41M 1.43% 27

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Silverarc Capital Management's ABOS Position: Q2 2023 in Review

Silverarc Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2023, closing a stake of 146,922 shares — an estimated $597K sold.

Silverarc Capital Management first reported a position in ABOS in Q3 2022 and held it in 3 quarters. The position peaked at $4.21M in Q3 2022. 53 funds tracked by Wall St. Rank hold ABOS as of Q2 2023.

  • Silverarc Capital Management reported no remaining Acumen Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 146,922 Acumen Pharmaceuticals shares in Q2 2023, an estimated $597K.
  • Silverarc Capital Management first reported a position in Acumen Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Silverarc Capital Management's Acumen Pharmaceuticals position peaked at $4.21M in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2023.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.